Adding Neoadjuvant Immunotherapy to Chemotherapy in Non-Metastatic Triple-Negative Breast Cancer: A Propensity-Matched Cohort Study from a Tertiary Cancer Center

Neoadjuvant pembrolizumab significantly enhances pathological response, reduces nodal involvement, and provides durable RFS and OS benefits in non-metastatic TNBC without increasing perioperative complications. This study supports incorporating immunotherapy into standard neoadjuvant regimens for TNBC patients and provides real-world evidence from a Middle Eastern tertiary cancer center.